BIIB
NASD Biogen Inc.$227.14 ↓ -1.55 (-0.68%) Trading Down from the previous close of $228.69
- YTD change
- +29.07%
- vs 20-day SMA
- +3.36%
- vs 200-day SMA
- +16.96%
Price ranges
Price & Performance
+41.12 (+21.92%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 51.5% away from all-time highs of $468.55
- BIIB is up 29% since the beginning of the year
- BIIB is up 64% over the past 12 months
- BIIB is up 4% over the past 1 month
- 4% of all BIIB investors are betting against BIIB
BIIB reads very good: price sits above both the 20- and 200-day averages, the 12-month move is +65.1%.
- Previous minute
- +$0.00
- Last hour
- +$0.00
- Last 5 days
- +3.69%
- vs 8-day SMA
- +1.56%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
